optically inactive 2,4-dipentyl-glutaric acid | 101083-39-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: optically inactive 2,4-dipentyl-glutaric acid
• 英文别名: Opt.-inakt. 2,4-Dipentyl-glutarsaeure；2,4-Dipentylpentanedioic acid
• CAS: 101083-39-0
• 化学式: C₁₅H₂₈O₄
• 分子量: 272.385
• InChiKey: QBFNRBYGUIAIBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  19
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 optically inactive 2,4-dipentyl-glutaric acid
  参考文献：
  名称：

  Eberson, Acta Chemica Scandinavica (1947), 1958, vol. 12, p. 314,321

  摘要：

  DOI：

文献信息

• Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
  申请人：——

  公开号：US20030040625A1

  公开（公告）日：2003-02-27

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstitutedpropanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.

  本发明提供了一类治疗化合物和方法，用于治疗患有生理紊乱的哺乳动物，例如经常出现的一种先天性高血压，这种生理紊乱与镁与细胞质膜结合力下降密切相关。这些方法包括向需要这种治疗的哺乳动物施用选自一系列二取代反式、反式 1，3-丁二烯、1，3-二取代全氢丁二烯、1，2-二取代反式乙烯和 1，2-二取代乙烷和二取代丙烷的化合物，其中每种化合物都共同体现了这些化合物的生物活性所必需的独特结构特征。本发明还提供了采用这些新型化合物的药物制剂。
• ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES
  申请人：Magnesium Diagnostics, Inc.

  公开号：EP1355638B1

  公开（公告）日：2006-05-03
• Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates
  申请人：Clifton Ibert

  公开号：US20070010535A1

  公开（公告）日：2007-01-11

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.
• Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
  申请人：Wells Clifton Ibert

  公开号：US20070197659A1

  公开（公告）日：2007-08-23

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.
• Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States
  申请人：WELLS IBERT CLIFTON

  公开号：US20110021633A1

  公开（公告）日：2011-01-27

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.